121.65
+2.2(+1.84%)
Currency In USD
| Previous Close | 119.45 |
| Open | 119.59 |
| Day High | 122.86 |
| Day Low | 118.1 |
| 52-Week High | 139.13 |
| 52-Week Low | 64.11 |
| Volume | 420,071 |
| Average Volume | 978,064 |
| Market Cap | 5.93B |
| PE | -20.34 |
| EPS | -5.98 |
| Moving Average 50 Days | 110.56 |
| Moving Average 200 Days | 93.17 |
| Change | 2.2 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $13,918.76 as of March 14, 2025 at a share price of $121.65. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $2,833.02 as of March 14, 2025 at a share price of $121.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
GlobeNewswire Inc.
Mar 05, 2025 12:00 PM GMT
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a set
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
GlobeNewswire Inc.
Mar 03, 2025 12:00 PM GMT
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous syste
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company lea